IBJNews

Lilly committed to China despite IP woes

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. will continue to build its business in China, even as it faces intellectual property theft, Lilly CEO John Lechleiter told Dow Jones Newswires in an interview published Nov. 20.

Indianapolis-based Lilly is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in their traditional U.S. and European markets.

China remains a small market for Lilly. It generated $320 million in sales for the company in 2010, just 1.3 percent of its $23 billion in sales worldwide. But China is expected to become the world’s third-largest pharmaceutical market this year and is projected to pass Japan and become the No. 2 market by 2015, according to IMS Health, a Connecticut-based pharmaceutical research firm.

In the third quarter, Lilly’s revenue from China grew 31percent, compared to 9 percent worldwide. Lilly drugs such as Zyprexa, which lost its western-market patents this year, and even Prozac, which has been off-patent for a decade, have been growing sales rapidly in China.

While the firm is also targeting markets in South Korea, Taiwan and Australia, China and Japan "are clearly our focus in Asia," Lechleiter told Dow Jones.

Lechleiter joined a group of other CEOs in a meeting with Chinese President Hu Jintao at the Asia Pacific Economic Cooperation summit in Hawaii this month. He said China has shown "remarkable progress" in anti-counterfeiting efforts, though he acknowledged that intellectual property theft remains a problem.

"The importance of intellectual property protection is understood by the highest levels of government in China," Lechleiter said, adding that officials realize stronger enforcement will be needed to protect China's own nascent industries.

Whereas in the past, intellectual property concerns made Lilly more reluctant than its peers to move aggressively into China, under Lechleiter the company has made major investments there. It has more than 3,000 employees in the country, and just opened a diabetes research center there to explore the unusual ways diabetes affects Chinese patients.

China's rapid economic growth has produced a burgeoning middle class, which now has the wealth to eat the diets and live the sedentary lifestyles common to westerners. The result is that more and more Chinese are developing the chronic illnesses that afflict prosperous societies, such as diabetes, heart disease and cancer.

"That plays into our strengths, and it means that we can expect to succeed with a portfolio of medicines in China that will look very similar to or the same as medicines that we have elsewhere in the world," Lechleiter said.

Lilly also is pressing Chinese authorities for more timely regulatory approval of innovative drugs, he said, and is pushing for betting representation of its drugs on health plan formularies in China, which can be biased in favor of generic or traditional therapies.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.

ADVERTISEMENT